Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Pharmacol
Asıl Yazarlar: Cecere, Sabrina C., Rossetti, Sabrina, Cavaliere, Carla, Della Pepa, Chiara, Di Napoli, Marilena, Crispo, Anna, Iovane, Gelsomina, Piscitelli, Raffaele, Sorrentino, Domenico, Ciliberto, Gennaro, Maiolino, Piera, Muto, Paolo, Perdonà, Sisto, Berretta, Massimiliano, Pignata, Sandro, Facchini, Gaetano, D'Aniello, Carmine
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2016
Konular:
Pharmacology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5005368/
https://ncbi.nlm.nih.gov/pubmed/27630568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00287
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller